NasdaqGM:HRMYPharmaceuticals
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)
Harmony Biosciences Holdings, Inc. reported past first-quarter 2026 results on May 7, with net income of US$32.49 million, down from US$45.56 million a year earlier, and basic earnings per share from continuing operations of US$0.56 versus US$0.79.
Alongside this earnings miss, the company highlighted 17% net product revenue growth, fresh FDA approval for a pediatric cataplexy indication, and active legal efforts to protect WAKIX patents into 2030.
We’ll now examine how robust revenue growth...